BriaCell Therapeutics Corp. Warrant

$0.0908 USD

-$0.01 (-9.11%)

Volume: 397.88K
Average Volume: 46.08K
Market Capitalization: $171.04K
P/E Ratio: -0.32
Dividend Yield: 0.00%
Price Target

Year High: $0.10
Year Low: $0.09
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $7.07

Industry, Sector & symbol

Stock Exchange	NASDAQ
CEO	William V. Williams
Industry	Biotechnology
Sector	Healthcare
Current Symbol	BCTXZ
CUSIP	107930117
CIK	0001610820
Web	https://www.briacell.com
Phone	604-921-1810
Currency	USD
Employees	16
Country	CA

Liquidity

Debt-to-Equity Ratio	0.00
Payout Ratio	0.00
Current Ratio	7.07
Quick Ratio	7.07
Cash Ratio	1.92

Sales & Book Value

Annual Sales	-$
Price / Sales	0.00
Cash Flow	-4.28
Price / Cash Flow	-0.24
Price / Book	1.18

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecast Upside/Downside	%
Consensus Rating	Sell
Rating Score(0-5)	2
Research Coverage	0 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$62.95
Trailing P/E Ratio	-0.32
PEG Ratio	0.00
P/E Growth	0.00
Net Income	-$26.63M
Net Margin	0.00%
Pretax Margin	0.00%
Return on Equity	-147.92%
Return on Assets	-113.23%

Financials Score

AltmanZ Score	-8.91
Piotroski Score	2.00
Working Capital	21.8M
Total Assets	27.07M
Ebit	-24.39M
Market Cap	240.75K
Total Liabilities	3.66M

Poll Results

About BriaCell Therapeutics Corp. Warrant (NASDAQ:BCTXZ) Stock

BriaCell Therapeutics Corp., a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, a personalized, ready-to-use immunotherapy intended for advanced breast cancer, and BriaDx, a diagnostic tool for determining patient HLA types. BriaCell maintains a non-exclusive clinical trial collaboration with Incyte Corporation to explore the effects of combining various novel clinical candidates. Furthermore, a cooperative research and develop ... ment agreement with the National Cancer Institute supports preclinical efforts to advance and test Bria-OTS cellular immunotherapy as a cancer therapy.

Frequently Asked Questions

What is the current BriaCell Therapeutics Corp. Warrant (BCTXZ) stock price?: BriaCell Therapeutics Corp. Warrant(NASDAQ:BCTXZ) stock price is $0.0908 in the last trading session. During the trading session, BCTXZ stock reached the peak price of $0.0995 while $0.0908 was the lowest point it dropped to. The percentage change in BCTXZ stock occurred in the recent session was --9.11% while the dollar amount for the price change in BCTXZ stock was -$0.01.
BCTXZ's industry and sector of operation?: The NASDAQ listed BCTXZ is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of BCTXZ?: Miguel A. Lopez-Lago | Chief Scientific Officer
Gadi Levin | Chief Financial Officer & Corporate Secretary
Giuseppe Del Priore | Chief Medical Officer
William V. Williams FCPA | Chief Executive Officer, President & Director
Charles Louis Wiseman FACP | Founder, Principal Research Advisor & Member of Scientific Advisory Board
How many employees does BCTXZ have?: Number of BCTXZ employees currently stands at 16. BCTXZ operates from Bellevue Centre, West Vancouver, BC V7T 2X1, CA.

Link for BCTXZ official website?: Official Website of BCTXZ is: https://www.briacell.com
How do I contact BCTXZ?: BCTXZ could be contacted at phone #604-921-1810 and can also be accessed through its website. BCTXZ operates from Bellevue Centre, West Vancouver, BC V7T 2X1, CA.
How many shares of BCTXZ are traded daily?: The average number of BCTXZ shares traded daily for last 3 months was 46.08K.
What is the market cap of BCTXZ currently?: The market value of BCTXZ currently stands at $171.04K with its latest stock price at $0.0908